BioValley News

29.11.2012

Lonza Signs Definitive Agreement for the Sale of Brandenburg, KY, Performance Urethanes and Organics business to Monument Chemical

Basel, Switzerland, and Indianapolis, IN (USA), 29 November 2012 – Lonza Group and Monument Chemical today announce the signing of a definitive agreement for the sale of substantially all of the assets of Lonza Group’s USA...[more]

29.11.2012

QIAGEN receives SFDA approval for marketing of healthcare HPV testing in China and expand access to HPV testing in resource-poor regions

Launch of care HPV testing in China and other emerging markets enables effective screening to prevent cervical cancerApproval in China as a manufacturing site of the tests is key is to spread to other countries, as it is a basis...[more]

29.11.2012

Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS

Long-term follow-up data from Jakavi® Phase III trials in patients with the debilitating blood cancer, myelofibrosisUpdated Phase III data in patients with Ph+ CML who switched to Tasigna® after long-term treatment with Glivec®...[more]

29.11.2012

10% of Straumann’s shares change ownership

Basel, Switzerland – 26 November 2012: Straumann Holding AG has been informed by two of its existing shareholders about a transaction involving a 10% block of registered shares. Dr h.c. Thomas Straumann, who is the major...[more]

22.11.2012

BioValley Stammtisch: CTI lessons learned - one year after the "Starker Franken" Projects

The next BioValley Stammtisch will take place on:Date:    Monday, 26 November 2012Time:    17.15 - 18.30, an apéro will be served after the presentationsLocation:    Biozentrum Basel,...[more]

22.11.2012

Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening when added to radiation and chemotherapy

Basel, 17 November 2012 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the positive phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy...[more]

22.11.2012

Actelion submits the registration dossier for macitentan (Opsumit) to the European Medicines Agency (EMA)

ALLSCHWIL/BASEL, SWITZERLAND - 22 November 2012 - Actelion (SIX: ATLN) today announced that the submission of the Marketing Authorisation Application (MAA) for macitentan (Opsumit®) for the treatment of patients with pulmonary...[more]

22.11.2012

LifeTech TaqMan Integrates with Genedata Expressionist for Genomic Profiling

Genedata partners with Life Technologies to expedite NGS data analysis and real-time PCR-based validation Basel, Switzerland -- November 14,  2012 -- Genedata, a leading provider of advanced software solutions for drug...[more]

22.11.2012

Dolomite launches the new Porous Media Chip providing rapid advances in petro-chemical research

Royston, UK (13th November 2012) – Dolomite, a world leader in microfluidic design and manufacture, has introduced the new Porous Media Chip, which enables statistically representative modelling of complex porous sandstone rock...[more]

22.11.2012

Auris Medical reporting positive results from phase IIb trial with AM-111 for the treatment of acute sensorineural hearing loss

November 13, 2012 – Auris Medical announced today positive results from a phase IIb clinical trial with AM-111, its investigational drug for the intratympanic (i.t.) treatment of acute sensorineural hearing loss (ASNHL). The...[more]

Displaying results 21 to 30 out of 1826

< Previous

1

2

3

4

5

6

7

8

9

10

Next >